- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 09.06. | SenzaGen AB: SenzaGen's subsidiary receives two orders within non-animal testing with a total value of SEK 2.4 million | 144 | GlobeNewswire (Europe) | SenzaGen's subsidiary VitroScreen has received two orders from existing customers for non-animal testing. The total order value amounts to SEK 2.4 million, with the majority of revenues expected to... ► Artikel lesen | |
| 12.05. | SenzaGen AB: Report from AGM of SenzaGen AB on 12 May 2026 | 240 | GlobeNewswire (Europe) | The Annual General Meeting (AGM) of SenzaGen held on today's date, 12 May 2026 in Lund, resolved to pass all proposals presented by the board and shareholders.
Adoption of income statement and balance... ► Artikel lesen | |
| 12.05. | SenzaGen AB: SenzaGen's interim report January-March 2026 | 10% sales growth alongside increased attention to non-animal methods | 211 | GlobeNewswire (Europe) | Message from the CEO"We started the year with 10 percent growth despite negative foreign exchange effects and the impact of a subsidiary undergoing a transition. At the same time, we maintained our... ► Artikel lesen | |
| 15.04. | SenzaGen AB: SenzaGen's subsidiary receives strategically important order | 251 | GlobeNewswire (Europe) | SenzaGens's subsidiary VitroScreen has received an order from an existing customer for non-animal efficacy testing. The order includes studies using the proprietary platform VitroScreenORA® and is carried... ► Artikel lesen | |
| SENZAGEN Aktie jetzt für 0€ handeln | |||||
| 31.03. | XFRA NEW INSTRUMENTS AVAILABLE ON 31.03.2026 | 561 | Xetra Newsboard | The following instruments on XETRA do have their first trading 31.03.2026 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 31.03.2026
Aktien
1 SE0009697204 Boho Group AB
2 SE0008321608... ► Artikel lesen | |
| 30.03. | SenzaGen AB: SenzaGen wins new global cosmetics group as customer | 223 | GlobeNewswire (Europe) | SenzaGen has received a first order from a leading global group in the cosmetics sector, one of the company's prioritized industry segments. The customer will begin by testing with GARD®skin Dose-Response... ► Artikel lesen | |
| 13.02. | SenzaGen AB: SenzaGen carries out a directed issue of approximately SEK 17.5 million to the institutional investor Eiffel Investment Group | 182 | GlobeNewswire (Europe) | THIS PRESS RELEASE MAY NOT BE ANNOUNCED, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND... ► Artikel lesen | |
| 13.02. | SenzaGen AB: SenzaGen's Year-End Report 2025 | SenzaGen closes the year with continued strong GARD sales | 239 | GlobeNewswire (Europe) | Message from the CEO
"As previously stated in the half-year report, 2025 performance was stronger in the second half of the year. GARD® continued to strengthen its market position with positive sales... ► Artikel lesen | |
| 16.12.25 | SenzaGen AB: SenzaGen further strengthens US market position with 1.5 MSEK order from global chemical industry leader | 198 | GlobeNewswire (Europe) | SenzaGen continues to solidify its role as an important partner for customers with high safety testing requirements, securing an assignment worth approximately 1.5 MSEK from a leading American chemical... ► Artikel lesen | |
| 20.11.25 | SenzaGen AB: SenzaGen opens expanded laboratory facilities to strengthen capacity in line with 2030 growth plan | 203 | GlobeNewswire (Europe) | To support its recently announced growth strategy through 2030, SenzaGen has opened expanded office and laboratory facilities in Lund. This investment strengthens the company's ability to meet the growing... ► Artikel lesen | |
| 18.11.25 | SenzaGen AB: UK signals shift to non-animal testing - new opportunities for SenzaGen | 207 | GlobeNewswire (Europe) | The UK government has recently unveiled a national strategy to accelerate the phase-out of animal testing in research and product development. The plan includes clear timelines and governance to ensure... ► Artikel lesen | |
| 05.11.25 | SenzaGen AB: SenzaGen's interim report January-September 2025 | Growth and break-even in Q3 | 188 | GlobeNewswire (Europe) | Message from the CEO"We delivered a strong third quarter in line with our expectations, with higher sales and significantly improved EBITDA, both sequentially and year on year, which I am pleased to... ► Artikel lesen | |
| 22.08.25 | SenzaGen AB: SenzaGen secures new follow-up order worth approx. 1.0 MSEK for GARD from a global leading U.S. pharmaceutical company | 265 | GlobeNewswire (Europe) | SenzaGen has received a new follow-up order from a global leader in the pharmaceutical and life science industry. The order, valued at approximately 1.0 million SEK, covers testing with GARD®air, SenzaGen's... ► Artikel lesen | |
| 20.08.25 | SenzaGen AB: SenzaGen's interim report January-June 2025 | Strong order intake and expanded OECD approval for GARDskin | 371 | GlobeNewswire (Europe) | Message from the CEO
"We continue to win new customers, and our order intake is significantly higher than our sales for the period, giving us a strong starting position for the coming quarters. Given... ► Artikel lesen |
14 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| DYNE THERAPEUTICS | 23,640 | 0,00 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces Expanded Debt Facility of Up To $400 Million with Hercules Capital, Inc. | - Up to $125 million in additional borrowing capacity provides further strategic flexibility - - $50 million of additional capacity funded at amendment closing - WALTHAM, Mass., June 17, 2026 (GLOBE... ► Artikel lesen | |
| EVOTEC | 3,677 | -25,60 % | Evotec-Aktie: Geht die Seitwärtsbewegung weiter? | Die Evotec-Aktie bewegt sich seit mehreren Wochen in einer engen Handelsspanne um die Marke von 5 €. Weder den Bullen noch den Bären ist bislang ein nachhaltiger Ausbruch gelungen. Am Mittwoch notiert... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 41,270 | 0,00 % | Servier completes the acquisition of Edgewise Therapeutics' Muscular Dystrophy Business | Acquisition supports Servier's strategic ambition in rare neurology with sevasemten, a late-stage investigational treatment for Becker and Duchenne muscular dystrophies. The acquired asset... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 110,55 | +0,14 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Appoints Elizabeth Laws, Ph.D., as Senior Vice President, Global Program Team Leader for KT-621, First-in-Class, Oral STAT6 Degrader | Dr. Laws, former immunology leader at Sanofi, will oversee global development of Kymera's KT-621 program KT-621 parallel Phase 2b trials advancing in AD and asthma, with data expected by year-end... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 314,34 | -0,07 % | Piper Sandler reiterates Praxis Precision Medicines stock rating | ||
| BEAM THERAPEUTICS | 30,990 | -0,03 % | BofA bestätigt Kaufempfehlung für Beam Therapeutics nach Schiedsspruch | ||
| TANGO THERAPEUTICS | 28,350 | -0,04 % | Krebs-Blockbuster-Medikament: Revolution Medicines: Auch Europa will das Medikament so schnell wie möglich! | © Foto: KI-generiert mit DALL-ENach starken Studiendaten aus den USA will nach der FDA auch Europas Arzneimittelbehörde das Medikament so schnell wie möglich zulassen. Revolution Medicines wird immer... ► Artikel lesen | |
| COGENT BIOSCIENCES | 37,480 | +0,05 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM) | Submission based on results of APEX pivotal trial which demonstrated bezuclastinib objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria with a well-tolerated... ► Artikel lesen | |
| VERA THERAPEUTICS | 41,505 | +0,01 % | Weekly Buzz: Johnson & Johnson, Vera Therapeutics Get FDA Nod; Vertex Pharmaceuticals Snaps Up Crinetics Pharmaceuticals; Satellos Bioscience Aces DMD Trial; Ionis Pharmaceuticals Misses Key Goal | NEW BRUNSWICK (dpa-AFX) - This week featured a steady stream of regulatory milestones, strategic dealmaking, and pivotal clinical trial updates, alongside missed trial goals across the biotech... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 133,79 | -0,02 % | Laufende Fusionskontrollverfahren: AbbVie Inc., North Chicago/Illinois/USA; Erwerb von Anteilen an und alleiniger Kontrolle über die Apogee Therapeutics, Inc., San Francisco/CA/USA | Datum der Anmeldung:07.07.2026Aktenzeichen:B3-76/26Unternehmen:AbbVie Inc., North Chicago/Illinois/USA; Erwerb von Anteilen an und alleiniger Kontrolle über die Apogee Therapeutics, Inc., San Francisco/CA/USAProduktmärkte:Biotechnologie... ► Artikel lesen | |
| CG ONCOLOGY | 72,55 | +0,07 % | CG Oncology Inc.: CG Oncology Reports Positive First Results from CORE-008 Cohort CX Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk BCG-Exposed and BCG-Unresponsive Patients | - High CR rates at any time observed in the CIS-containing population with 85.7% and 92.3% in the ITT population and Efficacy Evaluable population, respectively - High-Grade - EFS in the overall intention-to-treat... ► Artikel lesen | |
| TREVI THERAPEUTICS | 16,515 | -0,03 % | Trevi Therapeutics, Inc.: Trevi Therapeutics Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Updates | Following the End-of-Phase 2 meeting with the FDA, the Company gained alignment on its Phase 3 program for the treatment of patients with idiopathic pulmonary fibrosis-related chronic cough On track... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,295 | -0,15 % | Recursion Pharmaceuticals: Recursion Reports First Quarter Financial Results and Provides Business Update | Multiple milestones achieved or on track across wholly owned and partnered programs REC-1245 (RBM39 degrader): Early clinical data in solid tumors demonstrate a well-tolerated safety profile and predictable... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 15,300 | 0,00 % | Summit Therapeutics sells ridinilazole to Biossil for $500k | ||
| TARSUS PHARMACEUTICALS | 59,28 | -0,06 % | Tarsus Pharmaceuticals, Inc: Tarsus Pharmaceuticals Announces Executive Leadership Transition as Company Advances Next Phase of Growth | IRVINE, Calif., July 13, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) today announced that Aziz Mottiwala, Chief Commercial Officer, is departing the Company to pursue a new... ► Artikel lesen |
Das Unternehmen SENZAGEN AB kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 0,495 Euro und damit -1,39 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SENZAGEN AB finden Sie auf Wallstreet Online.